GSK Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Value Chain Analysis for Deeper Insight
This GSK Value Chain Analysis gives you a clear, company-specific view of how GSK creates value across support and primary activities. The page already shows a real preview of the actual analysis, so you can review the content and format before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
GSK's firm infrastructure steers capital, compliance, finance, risk, and legal controls across a 75+ country footprint. In 2025, GSK generated about £31bn in revenue and invested roughly £6bn in R&D, so tight oversight helps protect margin, patents, and launch timing. That matters because one quality slip or filing delay can hit sales in vaccines, specialty medicines, and general medicines fast.
Human Resource Management
GSK relies on scientists, clinical teams, manufacturing specialists, and commercial talent to keep its pipeline moving. In FY2024, GSK employed about 68,000 people and spent £6.3 billion on R&D, so hiring and retaining skilled staff directly supports faster innovation, tighter quality control, and smoother global launches. One bad hire in a regulated role can slow filings, batch release, and market access.
Technology Development
Technology development at GSK backs discovery platforms, clinical research, and manufacturing upgrades, helping turn science into faster launches. In 2025, GSK kept investing heavily in R&D, with spending in the billions of pounds, which supports pipeline productivity and data-led decisions across vaccines and specialty medicines. It also helps scale output with less quality and speed trade-off, especially in complex biologics.
Procurement
In 2025, GSK reported £31.4 billion in sales, so procurement of active ingredients, biologic inputs, packaging, lab services, and manufacturing materials has a direct impact on margin and supply continuity. Because these inputs come from a global supplier base, strong sourcing and supplier control help GSK reduce disruption risk, hold costs down, and keep regulated production running smoothly.
GSK's Support Engine Powers £31.4bn Growth
GSK's support activities keep a £31.4 billion 2025 business running across vaccines, specialty medicines, and general medicines. Firm infrastructure, talent, tech, and sourcing matter most because GSK spent about £6 billion on R&D and depends on regulated supply chains and fast filings. These functions cut delay risk, protect quality, and support margin.
| Support area | 2025 signal |
|---|---|
| Infrastructure | £31.4bn sales |
| People | ~68,000 employees |
| Technology | ~£6bn R&D spend |
| Procurement | Global regulated sourcing |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
GSK's inbound logistics rely on qualified suppliers for raw materials, biologic inputs, excipients, packaging, and trial supplies, with tight checks to protect traceability and cold-chain integrity. In FY2025, that control matters because GSK sold 300M+ vaccine doses and biologics need temperature-safe handling from receipt to site use. Careful inbound screening helps avoid stockouts, protect batch quality, and keep production moving.
Operations
GSK's Operations turn research into vaccines and specialty medicines through development, formulation, fill-finish, quality testing, and batch release. In 2025, GSK reported £31.4 billion in total sales, and its manufacturing scale helped deliver 1.4 billion vaccine doses worldwide. That value is created in Operations, where yield, compliance, and release speed decide whether a candidate becomes a reliable commercial supply.
Outbound Logistics
In FY2025, GSK moved finished drugs through wholesalers, hospitals, pharmacies, and public-sector channels across more than 100 markets, so outbound logistics has a direct impact on reach and revenue. Its vaccine and specialty-medicine flows need cold-chain control, usually 2°C to 8°C, to protect product quality and on-time delivery. That matters because even a short break in temperature control can damage high-value doses and raise write-offs.
Marketing and Sales
In 2025, GSK used medical affairs, field teams, and payer engagement to reach physicians, hospitals, governments, and distributors, helping support access in infectious diseases, HIV, oncology, and immunology. This sales engine matters because GSK reported 2025 turnover of about £31.4 billion, so even small gains in market access can move revenue. Strong payer and hospital coverage also helps GSK convert launches into prescriptions faster in high-value specialty markets.
Service
GSK's service activity covers safety monitoring, medical information, and product support after launch. Ongoing pharmacovigilance helps spot adverse events fast, meet regulator rules, and protect trust in medicines and vaccines. Strong customer support also lowers complaints and keeps adoption steady across hospitals, pharmacies, and clinics.
GSK FY2025: £31.4bn Sales and 1.4bn Vaccine Doses
In FY2025, GSK's primary activities centered on R&D, manufacturing, distribution, sales, and safety support. It reported £31.4 billion sales and delivered 1.4 billion vaccine doses, showing how Operations and outbound logistics turn science into supply. Strong field, payer, and pharmacovigilance teams help convert launches into prescriptions and protect product trust.
| FY2025 | Metric | Value |
|---|---|---|
| GSK | Sales | £31.4bn |
| GSK | Vaccine doses | 1.4bn |
Preview Before You Purchase
GSK Reference Sources
This is the actual GSK Value Chain Analysis document you'll receive upon purchase – no surprises, just a professional, ready-to-use report. The preview below is taken directly from the full version, so what you see is exactly what you get. Once purchased, the complete GSK Value Chain Analysis becomes available immediately.
Frequently Asked Questions
GSK's value chain emphasizes converting science into regulated products at scale. The model is anchored by 2 main platforms, vaccines and specialty medicines, and spans 4 therapy areas: infectious diseases, HIV, oncology, and immunology. That mix makes R&D, manufacturing, and market access the core value drivers.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.